Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Renowned Investment Bank Reiterates Buy Rating For Israeli Medical Company

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target: A Deep Dive into the Potential of $BLRX.
BioLine Rx (NASDAQ: $BLRX), an Israeli biopharmaceutical development company, recently received a reiterated buy rating from the renowned investment bank, HC Wainwright & Co. The financial institution has maintained a price target of $21 for BioLine Rx, indicating a positive outlook for the company's future. $BioLine Rx(BLRX.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
2032 Views
Comment
Sign in to post a comment
    121Followers
    0Following
    264Visitors
    Follow